SG11201700364PA - Novel glp-1 receptor modulators - Google Patents
Novel glp-1 receptor modulatorsInfo
- Publication number
- SG11201700364PA SG11201700364PA SG11201700364PA SG11201700364PA SG11201700364PA SG 11201700364P A SG11201700364P A SG 11201700364PA SG 11201700364P A SG11201700364P A SG 11201700364PA SG 11201700364P A SG11201700364P A SG 11201700364PA SG 11201700364P A SG11201700364P A SG 11201700364PA
- Authority
- SG
- Singapore
- Prior art keywords
- receptor modulators
- novel glp
- glp
- novel
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462028962P | 2014-07-25 | 2014-07-25 | |
| US201462090040P | 2014-12-10 | 2014-12-10 | |
| US201562161650P | 2015-05-14 | 2015-05-14 | |
| PCT/US2015/042114 WO2016015014A1 (en) | 2014-07-25 | 2015-07-24 | Novel glp-1 receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201700364PA true SG11201700364PA (en) | 2017-02-27 |
Family
ID=53777037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201700364PA SG11201700364PA (en) | 2014-07-25 | 2015-07-24 | Novel glp-1 receptor modulators |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9474755B2 (en) |
| EP (1) | EP3172199B1 (en) |
| JP (2) | JP6556237B2 (en) |
| KR (1) | KR102564946B1 (en) |
| CN (2) | CN112457301A (en) |
| AU (1) | AU2015292356B2 (en) |
| CA (1) | CA2955836C (en) |
| EA (1) | EA032525B1 (en) |
| ES (1) | ES2819534T3 (en) |
| IL (1) | IL249896B (en) |
| MX (1) | MX2017000972A (en) |
| SG (1) | SG11201700364PA (en) |
| WO (1) | WO2016015014A1 (en) |
| ZA (1) | ZA201700342B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2713722T (en) | 2011-05-31 | 2017-06-27 | Receptos Llc | Novel glp-1 receptor stabilizers and modulators |
| CA2913791A1 (en) | 2013-06-11 | 2014-12-18 | Receptos, Inc. | Novel glp-1 receptor modulators |
| EP3172199B1 (en) * | 2014-07-25 | 2020-07-01 | Celgene International II Sarl | Pyrimidine derivatives as glp-1 receptor modulators |
| AU2015360364B2 (en) * | 2014-12-10 | 2020-04-30 | Receptos Llc | GLP-1 receptor modulators |
| WO2018064476A1 (en) | 2016-09-30 | 2018-04-05 | Celgene International Ii Sarl | Dimethylaminoethanol salt of a glp-1 receptor modulator |
| AU2018260686B2 (en) * | 2017-04-28 | 2022-03-17 | Receptos Llc | Novel GLP-1 receptor modulators |
| WO2020210582A1 (en) * | 2019-04-11 | 2020-10-15 | University Of The Sciences | Allosteric agonists and positive allosteric modulators of glucagon-like peptide 1 receptor |
| CN112121152B (en) * | 2020-09-25 | 2021-06-22 | 南京大学 | Application of linatide in preparation of antitumor drugs |
| CN112898133B (en) * | 2021-01-27 | 2022-11-15 | 河北迈尔斯通电子材料有限公司 | Preparation method of trans-ketone intermediate |
| WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
| WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1062206B (en) | 1974-02-01 | 1983-09-20 | Rotta Research Lab S P A A S | THYROSIN DERIVATIVES ACTIVE ON SMOOTH MUSCLE |
| DE2423536A1 (en) | 1974-05-15 | 1975-11-27 | Bayer Ag | 3-AMINO-PHENYLACETIC ACID DERIVATIVES, THE PROCESS FOR THEIR PRODUCTION AND THEIR USE AS HERBICIDES |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| DK0996459T3 (en) | 1997-01-07 | 2006-01-16 | Amylin Pharmaceuticals Inc | Use of exendins and agonists thereof to reduce food intake |
| US6583139B1 (en) * | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| BR9811594A (en) | 1997-07-31 | 2000-09-05 | Elan Pharm Inc | Sulphonylated dipeptide compounds that inhibit vla-4 mediated leukocyte adhesion |
| RU2220950C2 (en) | 1997-08-22 | 2004-01-10 | Ф.Хоффманн-Ля Рош Аг | N-alkanoylphenylalanine derivatives |
| US6191171B1 (en) | 1997-11-20 | 2001-02-20 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
| IL143481A0 (en) | 1998-12-07 | 2002-04-21 | Sod Conseils Rech Applic | Glp-1 analogues |
| DE122007000001I1 (en) | 1999-01-14 | 2007-06-28 | Amylin Pharmaceuticals Inc | New exendin agonist formulations and their administration |
| RU2281283C2 (en) | 2000-03-07 | 2006-08-10 | Санофи-Авентис Дойчланд Гмбх | Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazole-2-ones and their using for inhibition of activity of hormone-sensitive lipase |
| AU2002350217A1 (en) | 2001-12-04 | 2003-06-17 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
| DE60332093D1 (en) | 2002-02-20 | 2010-05-27 | Ajinomoto Kk | NEW PHENYL ALANIDE DERIVATIVE |
| AU2004303696B2 (en) | 2003-12-22 | 2011-03-31 | Ea Pharma Co., Ltd. | Novel phenylalanine derivative |
| MXPA06009100A (en) * | 2004-02-10 | 2007-02-02 | Johnson & Johnson | Pyridazinones as antagonists of a4 integrins. |
| US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| WO2008112941A1 (en) | 2007-03-13 | 2008-09-18 | Board Of Regents The University Of Texas System | Composition and method for the treatment of diseases affected by a peptide receptor |
| WO2008149382A1 (en) | 2007-06-08 | 2008-12-11 | Advinus Therapeutics Private Limited | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application |
| US7727983B2 (en) * | 2008-03-07 | 2010-06-01 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds for the treatment of diabetes |
| CN102946882B (en) * | 2010-02-02 | 2016-05-18 | 格斯有限公司 | Phenylalamine derivatives and as the purposes of non-peptide GLP-1-1 receptor modulators |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| US8501982B2 (en) | 2010-06-09 | 2013-08-06 | Receptos, Inc. | GLP-1 receptor stabilizers and modulators |
| TWI523844B (en) * | 2011-01-26 | 2016-03-01 | 賽諾菲公司 | Amino-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
| PT2713722T (en) | 2011-05-31 | 2017-06-27 | Receptos Llc | Novel glp-1 receptor stabilizers and modulators |
| MX365923B (en) * | 2011-12-12 | 2019-06-20 | Celgene Int Ii Sarl | Carboxylic acid derivatives comprising four cycles acting as glp-1 receptor modulators for therapy of diseases such as diabetes. |
| CA2913791A1 (en) | 2013-06-11 | 2014-12-18 | Receptos, Inc. | Novel glp-1 receptor modulators |
| EP3172199B1 (en) * | 2014-07-25 | 2020-07-01 | Celgene International II Sarl | Pyrimidine derivatives as glp-1 receptor modulators |
-
2015
- 2015-07-24 EP EP15745738.3A patent/EP3172199B1/en active Active
- 2015-07-24 AU AU2015292356A patent/AU2015292356B2/en not_active Ceased
- 2015-07-24 KR KR1020177003172A patent/KR102564946B1/en active IP Right Grant
- 2015-07-24 CA CA2955836A patent/CA2955836C/en active Active
- 2015-07-24 SG SG11201700364PA patent/SG11201700364PA/en unknown
- 2015-07-24 US US14/809,020 patent/US9474755B2/en active Active
- 2015-07-24 MX MX2017000972A patent/MX2017000972A/en unknown
- 2015-07-24 CN CN202011261790.0A patent/CN112457301A/en active Pending
- 2015-07-24 CN CN201580046095.3A patent/CN107074820B/en active Active
- 2015-07-24 EA EA201790254A patent/EA032525B1/en not_active IP Right Cessation
- 2015-07-24 WO PCT/US2015/042114 patent/WO2016015014A1/en active Application Filing
- 2015-07-24 ES ES15745738T patent/ES2819534T3/en active Active
- 2015-07-24 JP JP2017525324A patent/JP6556237B2/en not_active Expired - Fee Related
-
2016
- 2016-09-13 US US15/263,637 patent/US9839664B2/en active Active
-
2017
- 2017-01-02 IL IL249896A patent/IL249896B/en active IP Right Grant
- 2017-01-16 ZA ZA2017/00342A patent/ZA201700342B/en unknown
-
2019
- 2019-06-10 JP JP2019107866A patent/JP2019142984A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US9474755B2 (en) | 2016-10-25 |
| ZA201700342B (en) | 2018-12-19 |
| US20160038487A1 (en) | 2016-02-11 |
| IL249896A0 (en) | 2017-03-30 |
| ES2819534T3 (en) | 2021-04-16 |
| EA032525B1 (en) | 2019-06-28 |
| KR20170040233A (en) | 2017-04-12 |
| MX2017000972A (en) | 2017-07-27 |
| AU2015292356B2 (en) | 2020-02-06 |
| CN107074820A (en) | 2017-08-18 |
| CA2955836A1 (en) | 2016-01-28 |
| JP2019142984A (en) | 2019-08-29 |
| JP2017526734A (en) | 2017-09-14 |
| EA201790254A1 (en) | 2017-07-31 |
| US20170216392A1 (en) | 2017-08-03 |
| CA2955836C (en) | 2023-02-14 |
| EP3172199B1 (en) | 2020-07-01 |
| KR102564946B1 (en) | 2023-08-08 |
| EP3172199A1 (en) | 2017-05-31 |
| IL249896B (en) | 2021-02-28 |
| CN112457301A (en) | 2021-03-09 |
| US9839664B2 (en) | 2017-12-12 |
| CN107074820B (en) | 2021-05-18 |
| JP6556237B2 (en) | 2019-08-07 |
| AU2015292356A1 (en) | 2017-02-02 |
| WO2016015014A1 (en) | 2016-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201605712B (en) | Therapeutic combinations with estrogen receptor modulators | |
| IL252257A0 (en) | Insulin receptor partial agonists | |
| ZA201700342B (en) | Novel glp-1 receptor modulators | |
| GB201514875D0 (en) | Receptor | |
| HK1252163A1 (en) | Receptor | |
| IL274537A (en) | Nuclear receptor modulators | |
| HK1222177A1 (en) | Novel glp-1 receptor modulators glp-1 | |
| EP3180332A4 (en) | Difluoropyrrolidines as orexin receptor modulators | |
| SG11201704080YA (en) | Optical modulator | |
| EP3215893C0 (en) | Electro-optic tile | |
| ZA201605332B (en) | Trpa1 modulators | |
| PL3303291T3 (en) | Ror-gamma modulators | |
| PL3303290T3 (en) | Ror-gamma modulators | |
| PL3303293T3 (en) | Ror-gamma modulators | |
| HRP20190024T1 (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
| EP3224261A4 (en) | Opioid receptor modulators | |
| GB2541589B (en) | Image modification | |
| PL3319942T3 (en) | Ror-gamma modulators | |
| GB201413262D0 (en) | Optical Apparatus | |
| IL252565B (en) | Novel glp-1 receptor modulators | |
| GB201404101D0 (en) | Image modification | |
| GB201512714D0 (en) | Receptor modulator compounds | |
| GB2529195B (en) | Optical apparatus | |
| GB201400215D0 (en) | Modulators | |
| GB201405403D0 (en) | Receptor modulation |